FDA experts offer a big thumbs up for J&J’s flawed application to market esketamine for major depression — but trial failures, safety questions spur concerns

J&J may have a deeply flawed application for its new/old drug to treat major depression, but the researchers who turned out to present the case for esketamine encountered a receptive audience of FDA experts on Tuesday.